

Boris Minev, M.D.

4587 Mercurio Street
San Diego, CA 92130
Phone: (858) 733-0037
Email: minevb@gmail.com

Curriculum Vitae

Professional Summary

Professional: President, Calidi Biotherapeutics, Inc. (2015-present); Volunteer Associate Clinical Professor, Department of Radiation Medicine and Applied Science, University of California San Diego (2017-present)

Education: Postdoctoral (Tumor Immunotherapy) Surgery Branch, National Cancer Institute (1992-1995); Postdoctoral (Tumor Immunotherapy) The Weizmann Institute, Israel (1990-1991); MD, Medical Academy, Sofia, Bulgaria (1988); BS, Biology, Medical Academy, Sofia (1984); Clinical Trials Administration Intensive Course at UC San Diego Extension (2015); Obtained the Clinical Trials Designs and Management Certificate (2016)

Highlights of Qualifications:

- Extensive clinical development experience with emphasis on early development
- Significant experience in clinical trial designs, logistics and regulatory issues
- Excellent skills in IND applications development and FDA interactions and communication
- Extensive experience in tumor immunology, T cell biology and cancer vaccine development
- Significant experience in immuno oncology and oncolytic immunotherapy of cancer
- Significant expertise in cancer stem cell targeting and nanotechnology-based cancer vaccines
- Considerable supervision & management experience
- Solid track record of corporate development, fundraising/corporate finance and investor relations

Leadership:

- As President of Calidi Biotherapeutics Inc., successfully lead clinical product development in Immuno Oncology, tumor immunotherapy, oncolytic vectors in immuno-oncology, and biomarker discovery and validation. Recruited World-renowned experts to Calidi's Scientific and Medical Advisory Board
- Develop and manage Calidi Biotherapeutics clinical activities, IND process and interactions with FDA and Immuno Oncology platform development
- Manage and coordinate activities with partners in Translational Medicine, Clinical Development, Biomarker Discovery and Development
- Identify appropriate immunotherapy targets, supervise preclinical and translational projects, design and supervise experiments and interpret data
- Manage business interactions and collaborations with industry and academic centers

Innovation:

- Successfully conceptualized, organized and executed Phase I clinical trial with the novel Calidi Biotherapeutics immuno-oncology platform based on stem cell-delivered oncolytic viruses.
- Developed and submitted several IND applications to FDA CBER
- Participated in the development of the first Canadian FDA-approved cancer vaccine "Melacine"
- Developed a new platform technology for delivery of biotherapeutics and immune enhancing agents utilizing biodegradable vaccine-loaded and targeted nanoparticles.

- Identified novel tumor target antigen-derived peptides, including telomerase, STEAP (six-transmembrane epithelial antigen of the prostate); oncofetal antigen (OFA); PRAME; and others

Personal:

Place of Birth: Plovdiv, Bulgaria (Dual USA & Bulgarian citizenship)

Languages: English, Bulgarian and Russian

Teamwork:

- Developed, coordinated and managed variety of joint projects with industry partners, including Johnson & Johnson, Geron Corporation, MediStem Corporation, Batu Biologics, Kirin Pharma USA, Triad Immunologies, SanRx Pharmaceuticals and others. This involves assuring accurate patient selection and clinical protocols development, selecting new targets, assuring new project starts, overseeing the discovery and development, and managing the project funds
- Developed and coordinated several joint projects with numerous academic and research institutions: Sidney Kimmel Cancer Center, Torrey Pines Institute for Molecular Studies, Clemson University, UC Riverside, San Diego State University and others.

Industry Consulting Activities

- **Amgen:** Provided an opportunity for medical affairs oncology personnel at Amgen to expand their knowledge base of tumor immunology
- **Johnson & Johnson:** Helped with the development of their melanoma vaccine program and Phase I clinical trial
- **GERON Corporation:** Provided expert opinion on improving their core technology – Induction of anti-tumor immune responses using embryonic stem cell-derived dendritic cells; Advised on development of complementary technology for antigen-loading based on nanotechnology
- **McKinsey Consulting:** Provided expert opinion about prospects for cancer vaccines
- **MAXX Genetech Co. Ltd.** Provided expert opinion on their core technology – novel therapeutic agents based on recently identified T cell receptor Vb families and common CDR3 sequences. Discussed their business development strategy in the US and China
- **TRIAD Immunologies/PrimeVax:** Provided expert opinion on their core technology – Combined Modality Therapy for melanoma; Helped with preclinical experimental design, data acquisition and analysis; Advised on their clinical program strategy and business development strategy in the US
- **Defined Health:** Provided expert opinion on two novel therapeutic vaccines for the treatment of malignant melanoma
- **Health Advances:** Advised on the implications of cancer vaccine targeting of a variety of different cancers, including prostate, breast, and melanoma, among others
- **Thomson Current Drugs:** Provided drug evaluation for Oncophage – a heat-shock protein based cancer vaccine developed by Antigenics, Inc.

Education

1984	B.S. Biology, Medical Academy, Sofia, Bulgaria
1988	M.D., Medical Academy, Sofia, Bulgaria
1991	Postdoctoral Fellowship - Tumor Immunotherapy The Weizmann Institute of Science, Rehovot, Israel
1992	Fogarty International Fellowship - Tumor Immunotherapy Experimental Immunology Branch National Cancer Institute, NIH, Bethesda, MD

1992-1994 Postdoctoral Fellowship - Tumor Immunotherapy
Surgery Branch, National Cancer Institute, NIH, Bethesda, MD

2016 Clinical Trials Designs and Management Certificate at UC San Diego Extension

Professional History

2015 to present: President, Calidi Biotherapeutics Inc.

Projects and Responsibilities:

- Directing all clinical activities at Calidi Biotherapeutics Inc.
- Designing and implementing all clinical trial strategies for Phase I and Phase II trials
- Overseeing IND applications and communications with the FDA
- Overseeing clinical trials, clinical data analysis and reporting
- Strategic planning and advising on all clinical programs and clinical budgets
- Actively interacting with outside corporate and academic clinical partners
- Working on corporate development, fundraising/corporate finance and investor relations

2017 to present: Volunteer Associate Clinical Professor, Department of Radiation Medicine and Applied Science, University of California San Diego

2010 to 2015: Director, Immunotherapy & Translational Oncology, Genelux Corporation

Projects and Responsibilities:

- Directing all Translational Oncology projects at Genelux Corporation
- Preparing Phase I clinical trial protocols and IND applications
- Advising on clinical trial designs, logistics and regulatory issues
- Overseeing all projects in immuno oncology and oncolytic immunotherapy of cancer
- Working on corporate development, fundraising/corporate finance and investor relations

2000 to 2014: Principal Investigator; Head, Laboratory of Tumor Immunology
UCSD Division of Neurosurgery and Cancer Center,
University of California, San Diego

1996 to 2000: Assistant Project Scientist
Cancer Center, University of California, San Diego

1995 to 1996 Postdoctoral Fellow, Center for Biological Therapy and Melanoma Research
Cancer Center, University of California, San Diego

1992-1994 Visiting Associate
Surgery Branch, National Cancer Institute, National Institutes of Health

1992 Fogarty International Fellow
Experimental Immunology Branch, National Cancer Institute, NIH

1991 European Association for Cancer Research Fellow
Israeli Ministry of Health Fellow
Department of Cell Biology
The Weizmann Institute of Science, Rehovot, Israel

1988-1991 Staff Oncologist, National Cancer Institute, Sofia, Bulgaria

Professional Affiliations

American Society for Clinical Oncology
Society for Immunotherapy of Cancer
European Association for Cancer Research
International Society for the Study of Comparative Oncology

Publications

Books and Book Chapters

Minev B. *Volume Editor*, Volume 10: Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Growth and Progression Book Series, Springer, 2011

Schroter S., Hayden M., Ma W., Rehan N., and **Minev B.** Cancer Vaccines. IN: Cancer Growth and Progression Book Series, Springer, 2011

Hayden M., Schroter S., Rehan N., Ma W., and **Minev B.** Trends in cancer vaccine research. IN: Trends in Cancer Research, Nova Science Publishers, Inc., 2011

Minev B. and Ma W. Melanocytic preneoplasia and melanoma vaccines. IN: Cancer Growth and Progression Book Series, Springer, 2012

Schroter S. and **Minev B.** Peptide based active immunotherapy in cancer. IN: Cancer Vaccines: Challenges and Opportunities in Translation, Edited by Adrian Bot and Mihail Obrocea, pp 109-129, Informa Healthcare, 2009

Minev B. and Salgaller M. Vaccines for the Immunotherapy of Prostate Cancer. IN: Handbook of Cancer Vaccines, Cancer Drug and Discovery Series. Edited by Beverly Teicher. pp. 451-464, The Humana Press, 2004.

Articles

Rationale for the Clinical Use of Adipose-Derived Mesenchymal Stem Cells for COVID-19 Patients. Rogers CJ, Harman RJ, Bunnell BA, Schreiber MA, Xiang X, Wang FS, Santidrian AF, **Minev, BR** J Transl Med. 2020;18(1):203.

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells.

Minev B, Lander E, Feller JF, Berman M, Greenwood BM, Minev I, Santidrian AF, Nguyen D, Draganov D, Killinc MO, Vyalkova A, Kesari S, McClay E, Carabulea G, Marincola FM, Butterfield LH, Szalay AA. J Transl Med. 2019 Aug 19;17(1):271.

Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8⁺ T cell immune responses.

Chen Q, Bao Y, Burner D, Kaushal S, Zhang Y, Mendoza T, Bouvet M, Ozkan C, **Minev B**, Ma W. *Drug Deliv Transl Res.* 2019 Dec;9(6):1095-1105.

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.

Draganov DD, Santidrian AF, Minev I, Nguyen D, Kilinc MO, Petrov I, Vyalkova A, Lander E, Berman M, **Minev B**, Szalay AA. *J Transl Med.* 2019 Mar 27;17(1):100.

Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer.

Chen Q, Yao L, Burner D, **Minev B**, Lu L, Wang M, Ma W. *Clin Transl Oncol.* 2019 Apr;21(4):433-442.

The ratio of ADSCs to HSC-progenitors in adipose tissue derived SVF may provide the key to predict the outcome of stem-cell therapy.

Kilinc MO, Santidrian A, Minev I, Toth R, Draganov D, Nguyen D, Lander E, Berman M, **Minev B**, Szalay AA. *Clin Transl Med.* 2018 Feb 7;7(1):5

Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.

Li H, Shao S, Cai J, Burner D, Lu L, Chen Q, **Minev B**, Ma W. *Immunology.* 2017 Nov;152(3):462-471

Humanized mice with subcutaneous human solid tumors for immune response analysis of vaccinia virus-mediated oncolysis.

Tsoneva D, **Minev B**, Frentzen A, Zhang Q, Wege A, Szalay AA. *Mol Ther Oncolytics.* 2017 June 16; 5:41-61

IFN γ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells.

Shao S, Risch E, Burner D, Lu L, **Minev B**, Ma W. *Int Immunopharmacol.* 2017 Apr 11;47:159-165.

Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells.

Kilinc MO, Ehrig K, Pessian M, **Minev BR**, Szalay AA. *J Transl Med.* 2016 Dec 20;14(1):340.

Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.

Huang T, Wang H, Chen NG, Frentzen A, **Minev B**, Szalay AA. *Mol Ther Oncolytics.* 2015 Mar 18;2:15003

Overcoming tumor immune evasion with an unique arbovirus.

Lyday B, Chen T, Kesari S, **Minev B**. *J Transl Med.* 2015 Jan 16;13:3.

TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant.

Saenz R, Fultalan D, Leutenez L, Eekhout F, Fecteau JF, Sundelius S, Sundqvist S, Larsson M, Hayashi T, **Minev B**, Carson D, Esener S, Messmer B, Messmer D.
J Transl Med. 2014 Aug 14;12:211.

Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.

Wagner SC, Markosian B, Ajili N, Dolan BR, Kim AJ, Alexandrescu DT, Dasanu CA, **Minev B**, Koropatnick J, Marincola FM, Riordan NH.
J Transl Med. 2014 May 13;12(1):127.

Oncolytic Virotherapy of Cancer: A Translational Oncology Approach at Genelux Corporation.

Minev B, Chen N, Yu Y, Stritzker J, Zhang Q, Duggal R, Cappello J, Fong Y, Lauer U, Szalay A
New Horizons in Translational Medicine, 2013; 1(1):10-15.

Functional role of solid tumor stem cells in disease etiology and susceptibility to therapeutic interventions.

Ramdass B, Duggal R, **Minev B**, Chowdhary A, Koka P.
J Stem Cells. 2013;8(3-4):189-231.

Biotherapeutic approaches to target cancer stem cells.

Duggal R, **Minev B**, Geissinger U, Wang H, Chen NG, Koka PS, Szalay AA.
J Stem Cells. 2013;8(3-4):135-49.

Optical detection and virotherapy of live metastatic tumor cells in body fluids with vaccinia strains.

Wang H, Chen NG, Minev BR, Zimmermann M, Aguilar RJ, Zhang Q, Sturm JB, Fend F, Yu YA, Cappello J, Lauer UM, Szalay AA.
PLoS One. 2013 Sep 3;8(9):e71105.

Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells.

Wang H, Chen NG, Minev BR, Szalay AA.
J Transl Med. 2012 Aug 17;10:167.

Characterization of iNOS(+) Neutrophil-like ring cell in tumor-bearing mice.

Virtuoso LP, Harden JL, Sotomayor P, Sigurdson WJ, Yoshimura F, Egilmez NK, **Minev B**, Kilinc MO.
J Transl Med. 2012 Jul 30;10:152.

Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety.

Rodriguez JP, Murphy MP, Hong S, Madrigal M, March KL, **Minev B**, Harman RJ, Chen CS, Timmons RB, Marleau AM, Riordan NH.
Int Arch Med. 2012 Feb 8;5:5.

Ma W, Chen M, Kaushal S, McElroy M, Zhang Y, Ozkan C, Bouvet M, and **Minev B**. PLGA Nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses.

Int. J. NanoMedicine 2012;7:1475-87

Ma W, Smith T, Bogin V, Zhang Y, Ozkan C, Ozkan M, Hayden M, Schroter S, Carrier E, Messmer D, Kumar V, and **Minev B**. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. J Transl Med. 2011 Mar 31;9:34.

Ichim TE, **Minev B**, Braciak T, Luna B, Hunninghake R, Mikirova NA, Jackson JA, Gonzalez MJ, Miranda-Massari JR, Alexandrescu DT, Dasanu CA, Bogin V, Ancans J, Stevens RB, Markosian B, Koropatnick J, Chen CS, Riordan NH. Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? *J Transl Med*. 2011 Mar 4;9:25.

Ichim TE, Solano F, Lara F, Paris E, Ugalde F, Paz Rodriguez J, **Minev B**, Bogin V, Ramos F, Woods EJ, Murphy MP, Patel AN, Harman RJ, Riordan NH. Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report. *Int Arch Med*. 2010 Nov 11;3(1):30.

Zhang M, Dias P, **Minev B**, Koka PS. Induction characterization and targeting of human hematopoietic cancer stem cells. *J Stem Cells*. 2010;5(1):1-7

Yang WZ, Zhang Y, Wu F, Min WP, **Minev B**, Zhang M, Luo XL, Ramos F, Ichim TE, Riordan NH, Hu X. Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. *J Transl Med*. 2010 Aug 3;8(1):75.

Clawson C, Huang CT, Futralan D, Martin Seible D, Saenz R, Larsson M, Ma W, **Minev B**, Zhang F, Ozkan M, Ozkan C, Esener S, Messmer D. Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. *Nanomedicine*. 2010 Mar 27.

Mikirova NA, Jackson JA, Hunninghake R, Kenyon J, Chan KW, Swindlehurst CA, **Minev B**, Patel AN, Murphy MP, Smith L, Ramos F, Ichim TE, Riordan NH. Augmentation of circulating endothelial progenitor cells and hematopoietic stem cells in human subjects. *J Transl Med*. 2010 Apr 8;8:34.

Ichim TE, Solano F, Lara F, Rodriguez JP, Cristea O, **Minev B**, Ramos F, Woods EJ, Murphy MP, Alexandrescu DT, Patel AN, Riordan NH. Combination stem cell therapy for heart failure. *Int Arch Med*. 2010 Apr 14;3(1):5.

Ichim TE, Harman RJ, Min WP, **Minev B**, Solano F, Rodriguez JP, Alexandrescu DT, De Necochea-Campion R, Hu X, Marleau AM, Riordan NH. Autologous stromal vascular fraction cells: a tool for facilitating tolerance in rheumatic disease. *Cell Immunol*. 2010;264(1):7-17. Epub 2010 Apr 8.

Mikirova NA, Jackson JA, Hunninghake R, Kenyon J, Chan KW, Swindlehurst CA, **Minev B**, Patel AN, Murphy MP, Smith L, Alexandrescu DT, Ichim TE, Riordan NH. Circulating endothelial progenitor cells: a new approach to anti-aging medicine? *J Transl Med*. 2009 Dec 15;7:106

Riordan NH, Ichim TE, Min WP, Wang H, Solano F, Lara F, Alfaro M, Rodriguez JP, Harman RJ, Patel AN, Murphy MP, Lee RR, and **Minev B**. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. *J Transl Med*. 2009 Apr 24;7(1):29.

Basak GW, Yasukawa S, Alfaro A, Halligan S, Srivastava AS, Min WP, **Minev B**, Carrier E. Human embryonic stem cells-derived blast cells express HLA-antigens. *J Transl Med*. 2009 Apr 22;7(1):27.

Zhong Z, Patel AN, Ichim TE, Riordan NH, Wang H, Min WP, Woods EJ, Reid M, Mansilla E, Marin GH, Drago H, Murphy MP, and **Minev B**. Feasibility investigation of allogeneic endometrial regenerative cells. *J Transl Med*. 2009 Feb 20;7:15.

Han X, Meng X, Yin Z, Rogers A, Zhong J, Rillema P, Jackson JA, Ichim TE, **Minev B**, Carrier E, Patel AN, Murphy MP, Min WP, Riordan NH. Inhibition of intracranial glioma growth by endometrial

regenerative cells. *Cell Cycle*. 2009 Feb 15;8(4):606-10. Epub 2009 Mar 2.

Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH, Riordan NH, Koropatnick J, **Minev BR**, Bogin V, Min WP, Tullis RH. Exosomes as a tumor immune escape mechanism: possible therapeutic implications. *J Transl Med*. 6(1):37, 2008

Zhang J., Eguchi J., Kruse C., Gomez G., Fakhrai H., Schroter S., Ma W., Hoa N., **Minev B.**, Delgado C., Wepsic H., Okada H. and Jadus M. Antigenic profiles of human glioma cell lines: Implications for patient CTL targeting of tumor associated antigens with allogeneic tumor cell-based vaccine or other immune-cell based therapies. *Clinical Cancer Research* 13: 566-575, 2007

Hayden M., Schroter S. and **Minev B.** Book review: analyzing T cell responses. *Cancer Immunology & Immunotherapy* 55 (12), 2006

Telusma G, Datta S, Mihajlov I, Ma W, Li J, Yang H, Newman W, Messmer BT, **Minev B**, Schmidt-Wolf IG, Tracey KJ, Chiorazzi N, Messmer D. Dendritic cell activating peptides induce distinct cytokine profiles. *Int. Immunol*. 18:1563-7, 2006

Yi P., Yu H., Ma W., Wang Q., **Minev B.** Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin. A dual-anchored tumor cell vaccine and its antitumor effect. *Cancer* 103: 1519-1528, 2005.

Moustafa M., Srivastava A., Nedelcu E., Donahue J., Gueorguieva I., Shenouda S., **Minev B.**, and Carrier E. Chimerism and Tolerance Post *In Utero* Transplantation with Embryonic Stem Cells. *Transplantation* 78: 1274-1282, 2004.

Minev B., Guo F., Gueorguieva I., and Sang R. A new target for immunotherapy of prostate cancer. *Anticancer Research* 24(5D): 3565-3566, 2004.

Minev B. Technology Evaluation: HSPPC-96, Antigenics, Inc. *Current Opinion in Molecular Therapeutics* 5(6): 680-686, 2003

Kaminski JM, Summers JB, Ward MB, Huber MR, **Minev B.** Immunotherapy and prostate cancer. *Cancer Treat Rev*. 2003 Jun; 29(3):199-209.

Lombardi V, Shnaar R, **Minev B**, Misasi R, Gitstsi Kh, Sorice M, Troncone A. Conjugates of aberrant gangliosides in antiglioma vaccine: toxicological assay. *Bull Exp Biol Med*. 2002 Oct;134(4):363-5.

Minev B., Guo F., Gueorguieva, I., Kaiser H. Vaccines for Immunotherapy of Breast Cancer and Prostate Cancer: New Developments and Comparative Aspects. *In vivo* 16: 405-416, 2002

Minev B. Melanoma Vaccines. *Seminars in Oncology* 29: 479-493, 2002

Minev B., Hipp J., Schmidt J., Firat H., Langlade-Demoyen P. and Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. *P.N.A.S.* 97: 4796-4801, 2000

Mitchell M.S., Kan-Mitchell J., **Minev B.**, Edman C., and Deans R. A novel melanoma gene (MG-50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T lymphocytes. *Cancer Research* 60: 6448-6456, 2000

Minev B., Chavez F., Dudouet, B. and Mitchell M.S. Synthetic signal sequences enhance Class I presentation of a peptide from the melanoma antigen MART-1. *Eur. J. Immunol.* 30: 2115-2124, 2000

Hipp J. D., Hipp J. A., Lyday B., and **Minev B.** Cancer Vaccines: An Update. *In Vivo* 14: 571-585, 2000

Minev B., and Hipp J. Cancer Vaccines: Enhancing class I presentation of HER2/neu-derived peptide antigens. *Cancer Detection & Prevention* 24: S209, 2000

Minev B., Chavez F., and Mitchell M.S. Cancer vaccines: novel approaches and new promise. *Pharmacology and Therapeutics* 81: 121-139, 1999

Minev B., Chavez F., and Mitchell M.S. New trends in the development of cancer vaccines. *IN VIVO* 12: 629-638, 1998

Minev B., Chavez F., and Mitchell M.S. Enhancing Class I antigen presentation by human dendritic cells loaded with fusion peptides. *Proceedings of the American Association for Cancer Research* 39: 173, 1998

Kaido T., Waterfield M., Dawid M., **Minev B.**, and Mitchell M. Type I and type II IFNs induce CTL recognition of an autologous melanoma variant resistant to CTL generated against the patient's first melanoma. *Journal of Interferon and Cytokine Research* 17: S105, 1997.

Chavez F., **Minev B.**, and Mitchell M.S. Improving the presentation of a human melanoma antigen by peptide modifications. *Journal of Investigative Medicine* 44: 136A, 1996

Minev B., Chavez F., and Mitchell M.S. Synthetic fusion peptides improve Class I presentation of a human melanoma antigen. *Proceedings of the American Association for Cancer Research* 37: 477, 1996

Minev B., Restifo N. Anticancer vaccines based on synthetic peptides. *Anticancer Research* 15: 5A, Abstr. p.1790, 1995

Minev B., Chavez F., and Mitchell M.S. Insertion signal sequence fused to minimal peptide improves the antigen presentation of a human melanoma antigen. *Anticancer Research* 15: 1791, 1995

Minev B., McFarland J., Spiess P., Rosenberg S., Restifo N. Insertion signal sequence fused to minimal peptides elicits specific CD8⁺ T cell responses and prolongs survival of thymoma-bearing mice. *Cancer Research* 54:4155-4161, 1994

Restifo N., **Minev B.**, Taggarse A., McFarland J., Wang M., Irvine K. Enhancing the recognition of tumor associated antigens. *Folia Biologica* 40:74-88, 1994

Minev B., Stoychkov J. Immune mechanisms in cancer metastasis. *Oncology* 28:35-38, 1991

Minev B., Valeva V., Kassabov K., Stoychkov J., Neichev H. Production of Interleukin I by respivax-stimulated peritoneal macrophages. *Comptes Rendus de l'Academie Bulgare des Sciences* 44:109-112, 1991

Minev B., Tsutsumansky I., Stoychkova N., Stoychkov L., Milev N. SOF/P - a new transplantable tumor model in BALB/c mice. *Oncology* 28:3-9, 1991

Kassabov K., Stoychkov J., **Minev B.**, Oral immunotherapy of spontaneous tumor metastases in mice with two human polyvalent vaccines. *Clinical and Experimental Metastasis* 10:121, 1992

Stoychkov J., Kassabov K., **Minev B.**, Oral human polyvaccines as inhibitors of solid tumor metastases in mice. *The European Journal of Cancer* 27: 38, 1991